Augmentation Review Stays Open as Clinics Report a Cautious Season

SEATTLE — At a licensed augmentation clinic in Seattle's Rainier Valley, the consent conversation has grown longer this year, and the reason sits in a regulator's file that has not closed. The safety review of Somaform Augmetics' neural-interface line remains open and contested, and clinicians say the uncertainty has made them slower, not idle. "We are not waiting for a verdict to be careful; we are being careful because there isn't one," said clinic director Dr. Priyanka Rao, who has paused elective neural procedures pending clearer guidance while continuing established somatic work. Roughly five percent of humans are now augmented, a share still climbing, and Rao's caseload reflects the split: robust demand for well-understood enhancements, hesitation at the contested frontier. Somaform founder Julian Morrow has defended the line as safe and urged patience with reviewers; regulators have neither cleared nor condemned it. For patients like machinist Milo Vance, weighing a neural interface for chronic pain, the open review is its own answer for now. "I can wait," he said. "The regulator waiting worries me more than the wait."